Ultomiris Market Expected to Grow Faster from 2026 to 2035
Understand this event
On October 10, 2026, IndexBox Supply Chain and Raw Materials published a report stating that the market for Ultomiris (ravulizumab-cwvz), a long-acting C5 inhibitor developed by Alexion and AstraZeneca Rare Disease, is projected to expand at a compound annual growth rate of 8.2% from 2026 to 2035, with the market index reaching 220 in 2035 (2025 = 100). The report attributed the growth to expanded indications and the rollout of a subcutaneous formulation. This report is currently the only source and is a secondary citation of an IndexBox report; the original report and official company documents were not provided. No earlier reports are available for comparison, so there are no discrepancies in the figures, timing, or claims. Progress remains at the forecast stage, with no further evidence of actual indication expansion or rollout of the subcutaneous formulation.
AI 根据报道生成 · 5 days ago更新
Impact and actions
AI compilation of public coverage, separating facts, inference and scenarios. Verify rules against the original sources.
IndexBox: Ultomiris market CAGR projected at 8.2% for 2026–2035
First update · Latest update (Beijing time)
Impact level
⚪ Background
What happened
IndexBox published a report on 2026-10-09 projecting a 2026–2035 CAGR of 8.2% for Ultomiris (ravulizumab-cwvz), a long-acting C5 inhibitor from Alexion/AstraZeneca’s rare disease division, and a 2035 market index of 220 (2025=100). Its approved indications are PNH, aHUS, gMG, and NMOSD; gMG was approved in 2022. Estimated demand shares are PNH 45%, aHUS 25%, gMG 15%, NMOSD 10%, and other 5%; estimated regional shares are North America 40% and Europe 30%. [1]
Involves:Ultomiris（ravulizumab-cwvz）
Seller impact
- InferenceInference: The report’s main assumptions behind projected growth are an increase in the share of the subcutaneous formulation and expansion of indications. It also notes that biosimilars, new complement inhibitors, and payer scrutiny could dampen growth in later years. These are all report estimates, not actual sales data. [1]
- InferenceInference: The report identifies cold-chain logistics and supply-chain resilience as key constraints, but does not provide shipping routes, carriers, temperature-control parameters, or freight cost data. The specific logistics stages and costs therefore cannot be quantified. [1]
Suggested action
If tracking this category, only verify the report’s methodology and actual Ultomiris sales and formulation data in AstraZeneca’s latest financial results; do not use this as a basis for procurement decisions.
Evidence that would disprove the assessment
- Assessment 1：If AstraZeneca’s financial results or regulatory disclosures show that Ultomiris’s actual sales growth, formulation mix, or indication scope differs substantially from the 8.2% projection and share assumptions, this assessment would no longer hold; the latest financial results should be checked within the next two weeks.
- Assessment 2：If a subsequent report discloses specific temperature-control requirements, carriers, or cold-chain surcharge data, this assessment that the logistics impact cannot be quantified should be revised.
Coverage timeline
Follow coverage to understand different perspectives.
- IndexBox Industry Chain and Raw MaterialsOriginal ↗Ultomiris drug market expected to grow faster by 2035, driven by expanded indications and the rollout of a subcutaneous formulation
According to an IndexBox report, the market for Ultomiris (ravulizumab-cwvz), a long-acting C5 inhibitor developed by Alexion and AstraZeneca Rare Disease, is projected to expand at a compound annual growth rate of 8.2% from 2026 to 2035, with the market index reaching 220 in 2035 (2025 = 100).
Interest trend for this event
Current interest 3·Comparable scope peak 9（10/10 07:00）·Change over 24 hours within comparable scope -49%
Trends compare the same continuously observed entities, which may be fewer than the current interest count. Move the pointer or select the chart to see hourly values; use arrow keys to navigate.